Form 8-K - Current report:
SEC Accession No. 0001493152-23-043098
Filing Date
2023-11-29
Accepted
2023-11-29 17:18:27
Documents
13
Period of Report
2023-11-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42872
  Complete submission text file 0001493152-23-043098.txt   270007

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE ptix-20231121.xsd EX-101.SCH 3796
3 XBRL DEFINITION FILE ptix-20231121_def.xml EX-101.DEF 28287
4 XBRL LABEL FILE ptix-20231121_lab.xml EX-101.LAB 37886
5 XBRL PRESENTATION FILE ptix-20231121_pre.xml EX-101.PRE 26499
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5837
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 231453332
SIC: 2834 Pharmaceutical Preparations